ORNBV Orion Oyj Class B

Orion Corporation: Managers’ transactions – Satu Ahomäki

Orion Corporation: Managers’ transactions – Satu Ahomäki

ORION CORPORATION      MANAGERS’ TRANSACTIONS 29 April 2020 at 15.30 EEST



Orion Corporation: Managers’ transactions – Satu Ahomäki

Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons.

Person subject to the notification requirement
Name:Ahomäki Satu 
Position:Other senior manager
   
Initial Notification 
Reference number:74370029VAHCXDR7B745_20200429140541_3
   
Issuer
Name:Orion Oyj
LEI:74370029VAHCXDR7B745
   
Transaction details
Transaction date:2020-04-29
Venue:NASDAQ HELSINKI LTD (XHEL)
Nature of the transaction:Disposal
Further details:Executed under portfolio or asset management
 
Instrument:Share
ISIN:FI0009014377
 
Volume:668
Unit price:47.45000 Euro
Volume:140
Unit price:47.45000 Euro
Volume:140
Unit price:47.45000 Euro
Volume:18
Unit price:47.45000 Euro
Volume:100
Unit price:47.45000 Euro
Volume:100
Unit price:47.45000 Euro
Volume:100
Unit price:47.45000 Euro
Volume:10
Unit price:47.45000 Euro
Volume:610
Unit price:47.45000 Euro
Volume:39
Unit price:47.45000 Euro
Volume:66
Unit price:47.45000 Euro
Volume:49
Unit price:47.46000 Euro
Volume:143
Unit price:47.47000 Euro
Volume:133
Unit price:47.45000 Euro
Volume:112
Unit price:47.45000 Euro
Volume:138
Unit price:47.47000 Euro
Volume:35
Unit price:47.50000 Euro
Volume:15
Unit price:47.50000 Euro
Volume:200
Unit price:47.50000 Euro
Volume:46
Unit price:47.51000 Euro
Volume:8
Unit price:47.51000 Euro
Volume:130
Unit price:47.51000 Euro
 
Aggregated transactions
Volume:3000
Volume weighted average price:47.45988 Euro

Orion Corporation

Timo LappalainenOlli Huotari
President and CEO   SVP, Corporate Functions

Publisher:

Orion Corporation

Communications

Orionintie 1A, FI-02200 Espoo

EN
29/04/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Orion Oyj Class B

 PRESS RELEASE

Orion announces agreement with Shilpa Medicare for Recombinant Human A...

Orion announces agreement with Shilpa Medicare for Recombinant Human Albumin for European market ORION CORPORATION PRESS RELEASE 23 MAY 2025 at 12.40 EEST         Orion announces agreement with Shilpa Medicare for Recombinant Human Albumin for European market Orion Corporation and Shilpa Biocare Private Limited, a fully-owned subsidiary of Shilpa Medicare Limited (“Shilpa”), have entered into an agreement to commercialise Recombinant Human Albumin in Europe. Recombinant Human Albumin is a key plasma protein used in various therapeutic applications. Shilpa’s Recombinant Human Albumin is ...

 PRESS RELEASE

Orion ja Shilpa Medicare sopimukseen rekombinantti ihmisseerumin album...

Orion ja Shilpa Medicare sopimukseen rekombinantti ihmisseerumin albumiini -tuotteen oikeuksista Euroopassa ORION OYJ        LEHDISTÖTIEDOTE        23.5.2025 KLO 12.40          Orion ja Shilpa Medicare sopimukseen rekombinantti ihmisseerumin albumiini -tuotteen oikeuksista Euroopassa Orion Oyj ja Shilpa Biocare Private Limited, joka on Shilpa Medicare Limitedin ("Shilpa") kokonaan omistama tytäryhtiö, ovat tehneet sopimuksen rekombinantti ihmisseerumin albumiini -tuotteen kaupallistamisesta Euroopassa. Rekombinantti ihmisseerumin albumiini on keskeinen plasmaproteiini, jota käytetään us...

 PRESS RELEASE

Orion to host Capital Markets Day today, 22 May 2025, in Helsinki

Orion to host Capital Markets Day today, 22 May 2025, in Helsinki ORION CORPORATION INVESTOR NEWS 22 MAY 2025 at 10.15 EEST         Orion to host Capital Markets Day today, 22 May 2025, in Helsinki Orion hosts its Capital Markets Day for analysts, institutional investors, bankers, and media representatives in Helsinki today, 22 May 2025. At the event, members of the Orion Executive Management Board will discuss Orion’s growth strategy, financial objectives, and businesses. Orion will not publish new strategic or financial targets in connection with the event. The presentation material...

 PRESS RELEASE

Orion järjestää pääomamarkkinapäivän tänään 22.5.2025 Helsingissä

Orion järjestää pääomamarkkinapäivän tänään 22.5.2025 Helsingissä ORION OYJ        LEHDISTÖTIEDOTE        22.5.2025 KLO 10.15         Orion järjestää pääomamarkkinapäivän tänään 22.5.2025 Helsingissä Orion järjestää pääomamarkkinapäivän analyytikoille, institutionaalisille sijoittajille, pankkiireille sekä tiedotusvälineiden edustajille Helsingissä tänään 22.5.2025. Tilaisuudessa Orionin johtoryhmän jäsenet puhuvat Orionin kasvustrategiasta, taloudellisista tavoitteista sekä liiketoiminnoista. Orion ei julkista uusia strategisia tai taloudellisia tavoitteita tilaisuuden yhteydessä. Es...

 PRESS RELEASE

Orion’s collaborator, MSD, expands clinical development program for op...

Orion’s collaborator, MSD, expands clinical development program for opevesostat to women’s cancers ORION CORPORATION INVESTOR NEWS 21 MAY 2025 at 07.30 EEST                    Orion’s collaborator, MSD, expands clinical development program for opevesostat to women’s cancers Orion’s collaborator, MSD, has expanded the development program for opevestostat (MK-5684) to now include women’s cancers. A new Phase 2 clinical trial evaluating the safety and efficacy of opevesostat for the treatment of breast, endometrial and ovarian cancers has been posted to ClinicalTrials.gov database. The stu...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch